NCT02249650View on ClinicalTrials.gov

To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

February 12, 2020

Study Completion Date

August 25, 2020

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

TSB-9-W1

Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.

Trial Locations (1)

33305

Chang Gung Medical Foundation, Taoyuan District

All Listed Sponsors
collaborator

Virginia Contract Research Organization Co., Ltd.

OTHER

lead

Taiwan Sunpan Biotechnology Development Co., Ltd.

OTHER

NCT02249650 - To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC. | Biotech Hunter | Biotech Hunter